TITLE

Drug Company Suppressed Data on Paroxetine-Induced Stimulation: Implications for Violence and Suicide

AUTHOR(S)
Breggin, Peter R.
PUB. DATE
November 2006
SOURCE
Ethical Human Psychology & Psychiatry;Fall2006, Vol. 8 Issue 3, p255
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the third product liability report about the California case Lacuzong versus GlaxoSmithKline (GSK). It mentions that both GSK and the U.S. Food and Drug Administration (FDA) have confirmed that the antidepressant drug Paxil causes increased suicidality in adults. It states that the report also addresses the role of Paxil-induced central nervous system stimulation in causing violence and suicide among patients.
ACCESSION #
25121055

 

Related Articles

  • Antidepressants for Children. Rlotter, Jule // Townsend Letter for Doctors & Patients;Oct2004, Issue 255, p20 

    Reports on the increase incidents of suicidal attempts and suicidal thoughts among patients under eighteen years old using antidepressant Paxil of GlaxoSmithKline PLC. Extended investigation of pediatric antidepressants by U. S. Food & Drug Administration; Uncertainty of the critics regarding...

  • FDA recommends against child use of Glaxo's Paxil for major depression.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p9 

    Reports on the recommendation of the U.S. Food and Drug Administration against child use of GlaxoSmithKline's antidepressant Paxil. Link between child use and risk of suicidal tendencies; Sales of the drug; Comparison between the drug and placebo.

  • ANTIDEPRESSANT UPS SUICIDE RISK IN ADULTS.  // Ecologist;Jul/Aug2006, Vol. 36 Issue 6, p14 

    The article reports that Seroxat can cause adults as well as children to become suicidal. Seroxat is the best-selling anti-depressant in the Great Britain. GlaxoSmithKline (GSK), manufacturer of Seroxat, has long been denying that there was a problem wit the drug. GSK was forced to admit the...

  • In Brief.  // Counseling Today;Jun2006, Vol. 48 Issue 12, p37 

    The article offers news briefs in the U.S. GlaxoSmith PLC and the U.S. Food and Drug Administration have warned medical practitioners that antidepressant Paxil can increase the risk of suicidal behavior in young adults. The U.S. National Center for Education Statistics has released a report...

  • GP registrar and my iPOD. Hague, John // Primary Care Mental Health;Jan2006, Vol. 4 Issue 1, p73 

    The article discusses the author's view on the issue of suicide attempts during antidepressant treatment. The author cites a survey of group health cooperative covering healthcare for a million people in the U.S. that questions the risk of death or serious suicide attempts and the drugs warned...

  • FDA mulls stronger warning for antidepressants. Johnsen, Michael // Drug Store News;10/11/2004, Vol. 26 Issue 13, p8 

    Reports on the issuance of a black-box warning on the use of antidepressants among children and adolescents by the U.S. Food and Drug Administration. Connection of antidepressants on suicidal behavior of children; Continuation of publicity and public awareness; Endorsement of a patient...

  • Link between FDA warnings and increased suicide questionable. Olfson, Mark; Schoenbaum, Michael // BMJ: British Medical Journal;10/11/2014, Vol. 349 Issue 7978, pg5614 

    A letter to the editor is presented in response to the article "Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study," by C. Y. Lu and colleagues in the June 18, 2014 issue.

  • Are study findings a false alarm? Barber, Catherine; Azrael, Deborah; Miller, Matthew // BMJ: British Medical Journal;10/11/2014, Vol. 349 Issue 7978, pg5645 

    A letter to the editor is presented in response to the article "Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study," by C. Y. Lu and colleagues in the 2014 issue.

  • Warning eyed for antidepressants.  // Drug Store News;9/27/2004, Vol. 26 Issue 12, p3 

    Reports on the recommendation of two Food and Drug Administration advisory committees to include a black-box warning in all antidepressant drugs related to an increased risk for suicidal ideation among pediatric patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics